Investigation of early and lifetime clinical features and comorbidities for the risk of developing treatment-resistant depression in a 13-year nationwide cohort study.

BMC Psychiatry
Shiau-Shian HuangPo-Hsiu Kuo

Abstract

To investigate the risk of treatment-resistant depression (TRD) in patients with depression by examining their clinical features, early prescription patterns, and early and lifetime comorbidities. In total, 31,422 depressive inpatients were followed-up from diagnostic onset for more than 10-years. Patients were diagnosed with TRD if their antidepressant treatment regimen was altered ≥two times or if they were admitted after at least two different antidepressant treatments. Multiple Cox regression model were used to determine whether physical and psychiatric comorbidities, psychosis, and prescription patterns increased the risk of TRD by controlling for relevant demographic covariates. Survival analyses were performed for important TRD-associated clinical variables. Females with depression (21.24%) were more likely to suffer from TRD than males (14.02%). Early anxiety disorders were more commonly observed in the TRD group than in the non-TRD group (81.48 vs. 58.96%, p < 0.0001). Lifetime anxiety disorders had the highest population attributable fraction (42.87%). Seventy percent of patients with multiple psychiatric comorbidities developed TRD during follow-up. Cox regression analysis further identified that functional gastroint...Continue Reading

References

Nov 1, 1991·Archives of General Psychiatry·J J Mann, S Kapur
Feb 1, 1989·The British Journal of Psychiatry : the Journal of Mental Science·M Hamilton
Mar 18, 2000·Clinical Psychology Review·T J TrullR Burr
Oct 23, 2001·Depression and Anxiety·E J LenzeC F Reynolds
Mar 14, 2003·The Journal of Clinical Psychiatry·Giovanni A Fava
Apr 11, 2003·Current Psychiatry Reports·Eric J Lenze
Aug 26, 2003·The Journal of Clinical Psychiatry·Maria A OquendoJ John Mann
May 17, 2005·Journal of Affective Disorders·A John RushMadhukar H Trivedi
Apr 28, 2006·Gender Medicine·Sushil K AhlawatG Richard Locke
Aug 10, 2007·The Journal of Clinical Psychiatry·Daniel SoueryUNKNOWN Group for the Study of Resistant Depression
Jun 17, 2008·Science & Practice Perspectives·Susan B QuelloSusan C Sonne
Feb 5, 2009·The Journal of Clinical Psychiatry·Abebaw FekaduAnthony J Cleare
Dec 22, 2009·Expert Review of Neurotherapeutics·Tom Bschor
Apr 13, 2010·Journal of Affective Disorders·Dominika DudekAndrzej Kiejna
Apr 22, 2011·Journal of Clinical Psychopharmacology·Paul N PfeifferMarcia Valenstein
Jul 28, 2011·BMC Medicine·Evelyn BrometRonald C Kessler
Oct 22, 2011·The British Journal of Psychiatry : the Journal of Mental Science·Cheng-Ta LiTung-Ping Su
Jan 6, 2012·Journal of Thyroid Research·Mirella P Hage, Sami T Azar
Dec 12, 2012·Journal of Affective Disorders·Ross J BaldessariniLeonardo Tondo
Feb 22, 2013·Lupus·L PalaginiS Bombardieri
Dec 10, 2013·Journal of Affective Disorders·Roger S McIntyreMaia Miguelez
Dec 20, 2013·The British Journal of General Practice : the Journal of the Royal College of General Practitioners·Laura ThomasNicola Wiles
Jan 16, 2014·Depression and Anxiety·Hanna M van LooRonald C Kessler
Mar 1, 2014·The Journal of Endocrinology·Rodrigo S FortunatoDenise P Carvalho
Jul 1, 2014·Psychosomatic Medicine·Lynn V DoeringMichael R Irwin
Oct 12, 2014·Journal of Affective Disorders·D BennabiE Haffen
Oct 16, 2015·Current Neuropharmacology·Rafael T de SousaRodrigo Machado-Vieira
Mar 25, 2016·BMC Psychiatry·Anke M BoeremaPim Cuijpers
May 3, 2016·The Journal of Clinical Psychiatry·Amir KrivoyGal Shoval
Nov 3, 2016·Journal of Clinical Psychopharmacology·Roberto Lewis-FernándezFranklin Schneier
May 12, 2017·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Tung-Ping SuJohn H Krystal
Mar 27, 2018·Lancet·Stephanie Clark, Richard Horton
May 23, 2018·Depression and Anxiety·M Soledad CepedaPatrick Ryan
Oct 28, 2018·The Lancet. Psychiatry·Louis NerurkarJonathan Cavanagh
Dec 20, 2018·Lancet·Jan Van ZundertKris Vissers

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here